KRAS and non-small cell lung carcinoma: In NSCLC, STK11/LKB1 mutations routinely occur, with an incidence of approximately 6%–13.6% (Shire et al., 2020), and approximately 7% of its mutation coexists with a KRAS mutation (Sumbly and Landry, 2022).